Singh D, et al. - A post hoc analysis of the FORWARD study was performed to determine the impacts of extrafine beclomethasone dipropionate (BDP)/formoterol fumarate (FF) in COPD patients with one exacerbation in the previous year, focusing on those categorized as group B using the GOLD 2017 definition. Findings revealed that treatment regimen comprising an inhaled corticosteroid (ICS) + long-acting β-agonist (LABA) vs LABA resulted in 35% reduction in exacerbation rate and hence, ICS-LABA treatment was proposed as a therapeutic option for COPD patients with one exacerbation in the previous year.